Loading market dashboard
Cardinal Health, Inc.
CAHHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
On June 04, 2026, Cardinal Health Inc (CAH) shares rose 3.0%, bringing the current price to $201.74. The stock has traded within a 52-week range of $137.75 to $
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Cardinal (CAH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CAH and COR are betting big on specialty pharma, but Cardinal Health???s stronger growth, raised outlook, and broader expansion may set it apart.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
CAH's fast-growing Other Growth Businesses posted 34% revenue growth and 52% profit gains, raising their role in long-term earnings.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cardinal Health's specialty growth, strong cash flow and expanding higher-margin businesses are boosting earnings momentum despite IRA and GMPD risks.
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
April 2026 delivered another major milestone for the portfolio. We posted an insane 80% year-over-year increase. In April 2026, I received $1,742.78 in dividend income compared to $968.18 in April 2025. Looking beyond just April, the full 2026 dividend income picture continues to trend dramatically ahead of 2025. The portfolio is producing significantly more cash flow through the first four months of the year.
Cardinal Health is expanding beyond drug distribution into specialty care, logistics and nuclear medicine, deepening its role in US healthcare infrastructure.
Kiplinger's Personal Finance May 2026 letter makes it clear that if you are looking for yield, the door is wide open across the entire risk spectrum. We are seeing a massive spread, with opportunities ranging from stable 3% municipal bonds to 13% for those willing to get aggressive with business development companies. This is unfolding... Kiplinger's May 2026 Letter Says Yields From 3% to 13% Are Available Right Now Despite Iran War Uncertainty
CAH shares are down 9.4% YTD, but strong specialty drug growth, rising earnings estimates and a raised outlook may signal upside.
Roughly a year ago, 24/7 Wall St. ran a piece titled Forget UnitedHealth.
Cardinal Health, Inc. (CAH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Cardinal Health's CAH Pharmaceutical & Specialty Solutions segment continues to be the primary engine of enterprise growth, delivering another standout quarter in the third quarter of fiscal 2026. Segment revenues climbed 19% to approximately $61 billion, while segment profit increased 29%, underscoring the segment's growing importance to Cardinal Health's earnings profile.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The heavy selling pressure might have exhausted for Cardinal (CAH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
DUBLIN, Ohio, May 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend to $0.5158 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2026 to shareholders of record at the close of business on July 1, 2026.
Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Cardinal (CAH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
As expected, Apple focused on share buybacks, increasing its share repurchase authorization by $100 billion while announcing a 4% dividend increase. Looking forward to the first half of May, Cardinal Health is expected to announce a modest 1–3% dividend increase, maintaining its pattern of minimal payout growth despite strong EPS expansion. Strong EPS growth—9% in 2025 and 23–25% projected for 2026—has not translated into higher dividend increases for CAH, as management prioritizes repurchases.
Cardinal Health, Inc. (CAH) Q3 2026 Earnings Call Transcript
Cardinal Health beats Q3 EPS estimates and raises 2026 outlook, fueled by pharma and specialty growth despite a revenue miss.
While the top- and bottom-line numbers for Cardinal (CAH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Cardinal Health (CAH) came out with quarterly earnings of $3.17 per share, beating the Zacks Consensus Estimate of $2.8 per share. This compares to earnings of $2.35 per share a year ago.
Cardinal Health raises its fiscal-year adjusted earnings guidance for the second time this year, helping investors look past mixed quarterly performance.
Cardinal Health once again raised its full-year outlook after logging higher-than-expected adjusted earnings in the third quarter.
Drug distributor Cardinal Health on Thursday raised its 2026 profit forecast range, betting on strong demand for costly specialty medicines and branded drugs at its pharmaceuticals unit.
Revenue increased 11% to $60.9 billion GAAP 1 operating earnings decreased 30% to $509 million; GAAP diluted EPS decreased 20% to $1.69 Non-GAAP operating earnings increased 18% to $956 million; non-GAAP diluted EPS increased 35% to $3.17 Cardinal Health raises and narrows fiscal year 2026 non-GAAP EPS guidance2 to $10.70 to $10.80 Cardinal Health reduces debt and completes additional $250 million share repurchase, bringing FY26 repurchase total to $1.0 billion DUBLIN, Ohio, April 30, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2026 revenues of $60.9 billion, an increase of 11% from the third quarter of fiscal year 2025. Third quarter GAAP operating earnings decreased 30% to $509 million and GAAP diluted earnings per share (EPS) decreased 20% to $1.69, reflecting a $184 million pre-tax goodwill impairment in the company's Navista & ION reporting unit primarily due to changes in the risk profile of the business plans resulting in an increase in the discount rate.
Comerica Bank cut its stake in Cardinal Health, Inc. (NYSE: CAH) by 10.5% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,658 shares of the company's stock after selling 7,235 shares during the period. Comerica Bank's holdings in Cardinal Health were
William Blair launched coverage of Cardinal Health (NYSE:CAH | CAH Price Prediction) with an Outperform rating today, framing the pharma distributor as a durable franchise with specialty-led upside.
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Besides Wall Street's top-and-bottom-line estimates for Cardinal (CAH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.
CAH's Q3 results are likely to benefit from strong specialty momentum and GMPD progress, but tougher comps and tariff pressures may test upside.
Abacus FCF Advisors LLC purchased a new position in Cardinal Health, Inc. (NYSE: CAH) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 34,950 shares of the company's stock, valued at approximately $7,182,000. Other large investors have also added
Somehow, members of Congress have turned relatively modest salaries into impressive investment portfolios while the rest of us grind it out in the market.
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
In the closing of the recent trading day, Cardinal Health (CAH) stood at $200.55, denoting a -2.13% move from the preceding trading day.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cardinal Health (CAH) reached $204.92 at the closing of the latest trading day, reflecting a -2.96% change compared to its last close.
ADM headlines a screen of broker-loved stocks as Q1 earnings begin and Strait of Hormuz-related issues impact oil and equities.
Here, we highlight three dental supplies stocks, CAH, COO and BDX, which are well positioned to generate wealth for investors amid macro uncertainty.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Cardinal Health, Inc. (NYSE: CAH) by 21.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,988 shares of the company's stock after purchasing an additional
Assetmark Inc. increased its stake in shares of Cardinal Health, Inc. (NYSE: CAH) by 14.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,139 shares of the company's stock after buying an additional 9,823 shares during the
In the latest trading session, Cardinal Health (CAH) closed at $211.83, marking a -1.45% move from the previous day.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Research confirms advanced therapies are moving beyond inpatient hospitals, with providers increasingly supporting partnerships that bring life-changing treatments closer to patients' homes. DUBLIN, Ohio, April 14, 2026 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2026 Advanced Therapies Report: Perspectives on Community Expansion, offering new insights into how the expanding advanced therapy pipeline is reshaping sites of care.
CAH's specialty growth, strong pharma demand and expanding services portfolio are driving earnings momentum and positioning it for sustained long-term growth.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FNY Investment Advisers LLC bought a new stake in shares of Cardinal Health, Inc. (NYSE: CAH) during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund bought 4,000 shares of the company's stock, valued at approximately $822,000. Other hedge funds have also made changes to
CAH expands Ac-225 capacity, boosting its role in radiopharma as rising clinical demand and future cancer therapy commercialization drive growth.
